These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20065653)

  • 61. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.
    Klein JS; Gnanapragasam PN; Galimidi RP; Foglesong CP; West AP; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2009 May; 106(18):7385-90. PubMed ID: 19372381
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP; Bryson S; Nieva JL; Pai EF
    J Mol Biol; 2008 Dec; 384(2):377-92. PubMed ID: 18824005
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.
    Cardoso RM; Zwick MB; Stanfield RL; Kunert R; Binley JM; Katinger H; Burton DR; Wilson IA
    Immunity; 2005 Feb; 22(2):163-73. PubMed ID: 15723805
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Antigp41 membrane proximal external region antibodies and the art of using the membrane for neutralization.
    Cerutti N; Loredo-Varela JL; Caillat C; Weissenhorn W
    Curr Opin HIV AIDS; 2017 May; 12(3):250-256. PubMed ID: 28422789
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Progress towards the development of a HIV-1 gp41-directed vaccine.
    McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
    Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.
    Miller MD; Geleziunas R; Bianchi E; Lennard S; Hrin R; Zhang H; Lu M; An Z; Ingallinella P; Finotto M; Mattu M; Finnefrock AC; Bramhill D; Cook J; Eckert DM; Hampton R; Patel M; Jarantow S; Joyce J; Ciliberto G; Cortese R; Lu P; Strohl W; Schleif W; McElhaugh M; Lane S; Lloyd C; Lowe D; Osbourn J; Vaughan T; Emini E; Barbato G; Kim PS; Hazuda DJ; Shiver JW; Pessi A
    Proc Natl Acad Sci U S A; 2005 Oct; 102(41):14759-64. PubMed ID: 16203977
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Exposure of the HIV-1 broadly neutralizing antibody 10E8 MPER epitope on the membrane surface by gp41 transmembrane domain scaffolds.
    Oakes V; Torralba J; Rujas E; Nieva JL; Domene C; Apellaniz B
    Biochim Biophys Acta Biomembr; 2018 Jun; 1860(6):1259-1271. PubMed ID: 29477358
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Crystal structure of a 3B3 variant--a broadly neutralizing HIV-1 scFv antibody.
    Clark KR; Walsh ST
    Protein Sci; 2009 Dec; 18(12):2429-41. PubMed ID: 19785005
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.
    Wang Y; Keck ZY; Saha A; Xia J; Conrad F; Lou J; Eckart M; Marks JD; Foung SKH
    J Biol Chem; 2011 Dec; 286(51):44218-44233. PubMed ID: 22002064
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies.
    Choudhry V; Zhang MY; Sidorov IA; Louis JM; Harris I; Dimitrov AS; Bouma P; Cham F; Choudhary A; Rybak SM; Fouts T; Montefiori DC; Broder CC; Quinnan GV; Dimitrov DS
    Virology; 2007 Jun; 363(1):79-90. PubMed ID: 17306322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
    Qi Z; Pan C; Lu H; Shui Y; Li L; Li X; Xu X; Liu S; Jiang S
    Biochem Biophys Res Commun; 2010 Jul; 398(3):506-12. PubMed ID: 20599765
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions.
    Neurath AR; Strick N; Lin K; Jiang S
    AIDS Res Hum Retroviruses; 1995 Jun; 11(6):687-96. PubMed ID: 7576928
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Role of HIV membrane in neutralization by two broadly neutralizing antibodies.
    Alam SM; Morelli M; Dennison SM; Liao HX; Zhang R; Xia SM; Rits-Volloch S; Sun L; Harrison SC; Haynes BF; Chen B
    Proc Natl Acad Sci U S A; 2009 Dec; 106(48):20234-9. PubMed ID: 19906992
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.
    Perez LG; Costa MR; Todd CA; Haynes BF; Montefiori DC
    J Virol; 2009 Aug; 83(15):7397-410. PubMed ID: 19458010
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Immunology. Close to the edge: neutralizing the HIV-1 envelope.
    Nabel GJ
    Science; 2005 Jun; 308(5730):1878-9. PubMed ID: 15976295
    [No Abstract]   [Full Text] [Related]  

  • 78. Construction and molecular characterization of mouse single-chain variable fragment antibodies against Burkholderia mallei and Burkholderia pseudomallei.
    Kim HS; Tsai S; Zou N; Lo SC; Wear DJ; Izadjoo MJ
    J Immunol Methods; 2011 Feb; 365(1-2):101-9. PubMed ID: 21172353
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies.
    Bruun TUJ; Tang S; Erwin G; Deis L; Fernandez D; Kim PS
    J Biol Chem; 2023 Apr; 299(4):103062. PubMed ID: 36841484
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Complexes of neutralizing and non-neutralizing affinity matured Fabs with a mimetic of the internal trimeric coiled-coil of HIV-1 gp41.
    Gustchina E; Li M; Ghirlando R; Schuck P; Louis JM; Pierson J; Rao P; Subramaniam S; Gustchina A; Clore GM; Wlodawer A
    PLoS One; 2013; 8(11):e78187. PubMed ID: 24244293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.